Literature DB >> 28483397

Short-Term Outcome of Intravenous Methylprednisolone Pulse Therapy in Patients With Infantile Spasms.

Hye-Ryun Yeh1, Min-Jee Kim1, Tae-Sung Ko1, Mi-Sun Yum2, Su-Jeong You3.   

Abstract

BACKGROUND: Many studies advocate hormonal treatments including high-dose oral prednisolone as an effective treatment for epileptic spasms. However, little is known about the effects of intravenous methylprednisolone pulse therapy on infantile spasms. We investigated the short-term response to intravenous methylprednisolone pulse therapy for the treatment of infantile spasms.
METHODS: Patients with newly diagnosed infantile spasms and hypsarrhythmia on electroencephalography (EEG) at two tertiary centers in Korea were included. Patients received intravenous infusions of 30 mg/kg/day methylprednisolone for three days with tapering doses of oral prednisolone for two to four weeks for the treatment of infantile spasms. Response to methylprednisolone pulse therapy was evaluated by seizure frequency and follow-up EEG within three weeks.
RESULTS: Fourteen patients were sudied. The mean age at the onset of spasms was 7.0 months (range, 2.0 to 11.0 months). Etiological factors included structural abnormalities (N = 11), chromosomal anomaly (N = 1), and unknown (N = 2). Nine of 14 participants (64.3%) demonstrated complete freedom from spasm and resolution of hypsarrhythmia on EEG within 3 weeks; however, only five of nine responders (55.5%) remained free of spasms after the discontinuation of oral steroids. Adverse effects, including irritability or infection, were observed in four patients but were tolerable in all.
CONCLUSIONS: Short-term methylprednisolone pulse therapy for the treatment of infantile spasms or hypsarrhythmia demonstrated rapid improvement in EEG and cessation of spasms without serious adverse effects. Further studies are needed to determine the long-term effects of spasm control.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  West syndrome; hypsarrhythmia; infantile spasms; methylprednisolone; short-term outcome; steroid

Mesh:

Substances:

Year:  2017        PMID: 28483397     DOI: 10.1016/j.pediatrneurol.2017.03.017

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  5 in total

Review 1.  Modeling epileptic spasms during infancy: Are we heading for the treatment yet?

Authors:  Libor Velíšek; Jana Velíšková
Journal:  Pharmacol Ther       Date:  2020-05-15       Impact factor: 12.310

2.  Intravenous Methylprednisolone Versus Oral Prednisolone for West Syndrome: A Randomized Open-Label Trial.

Authors:  Dipti Kapoor; Suvasini Sharma; Divyani Garg; Sukla Samaddar; Isha Panda; Bijoy Patra; Sharmila B Mukherjee; Harish K Pemde
Journal:  Indian J Pediatr       Date:  2021-02-11       Impact factor: 1.967

3.  Pulse Methylprednisolone with Oral Prednisolone versus Adrenocorticotropic Hormone in Children with West Syndrome: a Randomized Controlled Trial.

Authors:  Kanij Fatema; Mizanur Rahman; Mohammad Monir Hossain; Shaheen Akhter; Dewan Afsana Shomee; Sohela Akhter; Mazharul Mannan
Journal:  J Epilepsy Res       Date:  2021-12-31

4.  Safety and Effectiveness of Oral Methylprednisolone Therapy in Comparison With Intramuscular Adrenocorticotropic Hormone and Oral Prednisolone in Children With Infantile Spasms.

Authors:  Hong-Min Zhu; Chun-Hui Yuan; Meng-Qing Luo; Xiao-Long Deng; Sheng Huang; Ge-Fei Wu; Jia-Sheng Hu; Cong Yao; Zhi-Sheng Liu
Journal:  Front Neurol       Date:  2021-12-22       Impact factor: 4.003

5.  Effectiveness of corticosteroids versus adrenocorticotropic hormone for infantile spasms: a systematic review and meta-analysis.

Authors:  Yin-Hsi Chang; Chiehfeng Chen; Shu-Huey Chen; Yu-Chun Shen; Yung-Ting Kuo
Journal:  Ann Clin Transl Neurol       Date:  2019-10-27       Impact factor: 4.511

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.